Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)
Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMVPeriodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV: A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with Letermovir
Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV: A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with LTV
Study summary
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe in preventing this infection, although it may be associated with a delay in CMV-specific immune reconstitution. Hence, it is needed a study to evaluate whether the absence of CMV-specific immune reconstitution at the end of LTV prophylaxis is associated with the development of late infection. This could facilitate the individualization of CMV prophylaxis duration in these patients.
Methods and analysis: INMUNOEND is a multicenter, prospective, observational, non-interventional study including CMV seropositive patients undergoing allo-SCT who receive LTV prophylaxis during the first 100 days post-SCT. Immunological and virological monitorization will be conducted until day +200 post-SCT. The primary outcome variable is the percentage of patients who develop clinically significant CMV infection up to day +200 post-SCT after completing LTV prophylaxis. Data collected will include: baseline characteristics of the hematological diseases and comorbidities, variables related to SCT (i.e. engrafment, graft-versus-host disease, use of letermovir and CMV replication) and variables related to CMV-specific immune reconstitution.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age \>18 years.
* CMV seropositivity (positive IgG) in the recipient at the time of SCT.
* First allogeneic hematopoietic stem cell transplant recipient (bone marrow, peripheral blood, or cord blood).
* Within the first 28 days post-SCT at the time of inclusion.
* Indication for LTV prophylaxis within the first 28 days post-transplant up to 100 days post-SCT, according to the criteria established in each center.
Exclusion Criteria:
* CMV seronegativity (negative IgG) in the recipient at the time of transplant.
* Previous allogeneic stem cell transplant (patients with a prior autologous transplant are allowed to be included).
* History of CMV disease in the 6 months prior to inclusion.
* Need for preemptive therapy in the month prior to inclusion in the study.
* Received any of the following in the 14 days prior to inclusion: Ganciclovir, valganciclovir, foscarnet, acyclovir (at doses \>3200 mg orally per day or \>25 mg/kg IV per day), valacyclovir (at doses \>3000 mg orally per day), famciclovir (at doses \>1500 mg orally per day).
* Received any of the following in the 30 days prior to screening: Cidofovir, CMV hyperimmune immunoglobulin, any CMV antiviral in the investigational phase.
* Suspected or confirmed hypersensitivity reaction to the LTV formulation or any of its components.
* Severe hepatic insufficiency (defined as Child-Pugh class C).
* History of primary immunodeficiency prior to transplant.
* Participation in a clinical trial involving the administration of CMV vaccines, other investigational CMV drugs, or monoclonal antibodies.
Primary outcome measure(s)
percentage of patients who develop clinically significant CMV infection (CMV-Cs) up to day +200 post-SCT after completing LTV prophylaxis — From enrollment to 200 days post-SCT
Trial sites (1)
Facility
City
Region
Status
Hospital Universitario Reina Sofía
Córdoba
Córdoba
More Maimónides Biomedical Research Institute of Córdoba trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
